NCT02817451View on ClinicalTrials.gov

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 14, 2016

Primary Completion Date

February 22, 2019

Study Completion Date

February 22, 2019

Conditions
DiphtheriaTetanusPertussisHepatitis BPolioHuman Immunodeficiency Virus Infection
Interventions
BIOLOGICAL

Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine

0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months

BIOLOGICAL

Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine

0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months

Trial Locations (1)

Unknown

Soweto

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02817451 - DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants | Biotech Hunter | Biotech Hunter